SHANGHAI, September 19, 2022 /PRNewswire/ — Everest Medicines (HKEX 1952.HK, “Everest” or the “Company”), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products to address critical unmet needs in Asia Pacific Markets, announced the appointment of Rogers Yongqing Luo as the company’s Chief Executive Officer, effective immediately. Mr. Luo will also serve as Executive Director on Everest’s Board of Directors.
Mr. Luo brings to Everest more than 25 years of healthcare industry experience with an extensive leadership track record in clinical development, regulatory affairs and commercialization. Previously, Mr. Luo served as President and General Manager, Greater China at Brii Biosciences and CEO of TSB Therapeutics, where he led the rapid approval, GMP certification and successful commercialization of the amubarvimab/romlusevimab combination, the first COVID-19 neutralizing antibody treatment China. Prior to that, he was Global Vice President and China General Manager at Gilead Sciences, where he led the clinical development, regulatory approval and successful commercialization of eight innovative therapeutics and efforts that rapidly expanded patient access China. Mr. Luo previously oversaw the successful launch of several high-profile drugs. He managed sales, marketing, government affairs and market access functions for various leading multinational pharmaceutical companies, including Roche and Novartis, and worked at Novartis headquarters for two years Switzerland.
“As Everest Medicines continues to evolve its business strategy and rapidly expand our novel product pipeline, we are excited to have Rogers join the Company to lead Everest through its next phase of growth into a fully integrated biopharmaceutical company China‘ said Mr. Wei Fu, Chairman of the Board of Everest Medicines and Chief Executive Officer of the CBC Group. “With a solid background as a top executive in both biotech startups and large multinational pharmaceutical companies, Rogers brings to Everest a unique set of expertise, including deep scientific insight, proven leadership and commercialization excellence in patient access, and a proven track record of advancing the community innovative early- and late-stage pipeline to commercial launch in Greater China. In particular, Rogers’ leadership will strengthen Everest’s new product development and commercial capabilities as we work toward potential late-stage approvals of our anchor product candidates, including Nefecon, Xerava, Etrasimod and mRNA vaccines. We look forward to leveraging Rogers’ leadership and industry expertise to generate long-term growth and success across the business.”
“I am extremely excited to join Everest and look forward to working with this talented team of world-class scientists and industry experts to expand the company’s industry leadership. Based on our strong balance sheet, we are committed to entering into synergistic business development agreements to advance our journey to becoming an integrated biopharmaceutical company to accelerate,” said Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines. “We will continue to invest in our research platform to build an innovative therapeutic pipeline to benefit patients with unmet needs Greater China and other Asia Pacific markets and to create sustainable and long-term value for our shareholders.”
About Everest Medicines
Everest Medicines is a biopharmaceutical company focused on the development and commercialization of transformative pharmaceutical products that address critical, unmet medical needs for patients in Asian markets. Everest Medicines’ management team has deep expertise and an extensive track record in high quality clinical development, regulatory affairs, CMC, business development and operations China and with leading global pharmaceutical companies. Everest Medicines has built a portfolio of potentially global first-in-class or best-in-class molecules, many of which are in late-stage clinical development. The company’s therapeutic areas of interest include oncology, autoimmune diseases, cardio-renal diseases and infectious diseases. Visit www.everestmedicines.com for more information.
This press release may contain statements that constitute forward-looking statements, including descriptions of the Company’s or its officers’ intentions, beliefs or current expectations regarding the Company’s operations and financial condition, represented by terminology such as “will”, “expected” , “anticipates”, “future”, “intends”, “plans”, “believes”, “estimates”, “confident” and similar statements. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties or other factors, some of which are beyond the Company’s control and are unpredictable. Therefore, actual results may vary based on various factors and assumptions, such as B. future changes and developments in our business, competitive environment, political, economic, legal and social conditions, differ from those contained in the forward-looking statements. The Company or its affiliates, directors, officers, consultants or agents have no obligation and undertake no obligation to revise any forward-looking statements to reflect new information, future events or circumstances after the date of this press release, except to the extent required by law required .